Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2231151 | 0.82 | PIM1 (0.42) | PIM1ACKR3ALOX15 | |
| SCHEMBL1186740 | 0.82 | — | — | |
| SCHEMBL6852451 | 0.79 | PIM1 (0.35) | PIM1ACKR3ALOX15ACHEP2RX7 | |
| SCHEMBL1306357 | 0.79 | ALDH1A1 (0.43) | PIM1ACKR3ALOX15 | |
| SCHEMBL8424491 | 0.76 | — | — | |
| SCHEMBL14940714 | 0.76 | DRD2 (0.39) | — | |
| SCHEMBL475176 | 0.75 | NPSR1 (0.41) | — | |
| SCHEMBL14142584 | 0.75 | PIM1 (0.39) | PIM1 | |
| SCHEMBL134397 | 0.75 | PIM1 (0.39) | PIM1 | |
| SCHEMBL19212956 | 0.75 | PIM1 (0.39) | PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953853-B2 | Phospholipase inhbitors; antiinflammatory agents; respiratory system disorders | ALTANA PHARMA AG (DE) | 2005-10-11 | — | — | US | claimed |
| US-20040067946-A1 | Phthalatyinone-piperidino-derivatives as pde4 inhibitors | TAKEDA GMBH (DE) | 2004-04-08 | — | — | US | claimed |
| EP-1362044-A1 | PHTHALAZINONE-PIPERIDINO-DERIVATIVES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2003-11-19 | — | — | EP | claimed |
| WO-2002064584-A1 | PHTHALAYINONE-PIPERIDINO-DERIVATIVES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2002-08-22 | — | — | WO | claimed |
| US-7531540-B2 | Phthalazinone-piperidino-derivatives as PDE4 inhibitors | NYCOMED GMBH (DE) | 2009-05-12 | — | — | US | disclosed |
| US-20070129373-A1 | Phthalazinone-piperidino-derivatives as PDE4 inhibitors | ALTANA PHARMA AG | 2007-06-07 | — | — | US | disclosed |
| US-20060148804-A1 | Pde4 inhibitors for the treatment of neoplasms of lymphoid cells | NYCOMED GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| US-20050234062-A1 | Phthalazinone-piperidino-derivatives as PDE4 inhibitors | ALTANA PHARMA AG | 2005-10-20 | — | — | US | disclosed |
| US-6953853-B2 | Phospholipase inhbitors; antiinflammatory agents; respiratory system disorders | ALTANA PHARMA AG (DE) | 2005-10-11 | — | — | US | disclosed |
| US-20040067946-A1 | Phthalatyinone-piperidino-derivatives as pde4 inhibitors | TAKEDA GMBH (DE) | 2004-04-08 | — | — | US | disclosed |
| EP-1362044-A1 | PHTHALAZINONE-PIPERIDINO-DERIVATIVES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002064584-A1 | PHTHALAYINONE-PIPERIDINO-DERIVATIVES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148804-A1 | Pde4 inhibitors for the treatment of neoplasms of lymphoid cells | PDE4A, PDE4B, PDE4C | PIM1 461/4885ACKR3 356/4885ALOX15 1648/4885 |
| US-20040067946-A1 | Phthalatyinone-piperidino-derivatives as pde4 inhibitors | PDE4A, PDE4B, PDE5A | PIM1 3011/4885ACKR3 2237/4885ALOX15 3234/4885 |
| US-20070129373-A1 | Phthalazinone-piperidino-derivatives as PDE4 inhibitors | PDE4A, PDE4B, PDE5A | PIM1 3010/4885ACKR3 2463/4885ALOX15 3361/4885 |
| US-20050234062-A1 | Phthalazinone-piperidino-derivatives as PDE4 inhibitors | PDE4A, PDE4B, PDE5A | PIM1 3010/4885ACKR3 2463/4885ALOX15 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.